

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

NCI-H446

RRID:CVCL_1562

Type: Cell Line

Proper Citation

RRID:CVCL_1562

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1562

Proper Citation: RRID:CVCL_1562

Description: Cell line NCI-H446 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung small cell carcinoma

Defining Citation: [PMID:1320893](#), [PMID:1563005](#), [PMID:2985257](#), [PMID:2985258](#), [PMID:6148444](#), [PMID:6713399](#), [PMID:8626706](#), [PMID:8806092](#), [PMID:8806103](#), [PMID:11030152](#), [PMID:16677475](#), [PMID:17426248](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20193106](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:21163134](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:23716474](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:26676926](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28599409](#), [PMID:28766886](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:32351780](#), [PMID:32586373](#), [PMID:35839778](#), [PMID:39154123](#)

Comments: Karyotypic information: Hypertriploid karyotype., Population: Caucasian., Part of: MYC genetic alteration cell panel (ATCC TCP-1035)., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H446

Synonyms: H446, H-446, NCI-446, NCIH446

Cross References: CLO:CLO_0008088, EFO:EFO_0002293, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-171, BioGRID_ORCS_Cell_line:806, BioSample:SAMN03473283, BioSample:SAMN10988349, cancercellines:CVCL_1562, CCRID:1101HUM-PUMC000082, CCRID:3101HUMTCHu196, Cell_Model_Passport:SIDM00965, ChEMBL-Cells:ChEMBL3307760, ChEMBL-Targets:ChEMBL612440, CLS:305049, Cosmic:688023, Cosmic:755465, Cosmic:801352, Cosmic:844554, Cosmic:877357, Cosmic:897516, Cosmic:929976, Cosmic:932947, Cosmic:1006526, Cosmic:1021863, Cosmic:1152471, Cosmic:1219102, Cosmic:1239939, Cosmic:1434963, Cosmic:1995578, Cosmic:2125198, Cosmic:2664127, Cosmic:2668272, Cosmic-CLP:688023, DepMap:ACH-000800, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:688023, GEO:GSM169448, GEO:GSM380477, GEO:GSM784254, GEO:GSM845547, GEO:GSM887429, GEO:GSM888509, GEO:GSM1670244, GEO:GSM1682798, GEO:GSM1887892, GEO:GSM1887975, IARC_TP53:21573, IGRhCellID:NCIH446, KCB:KCB 200688YJ, LiGeA:CCLE_177, LINCS_LDP:LCL-1855, PharmacDB:NCIH446_1113_2019, PRIDE:PXD011896, PRIDE:PXD015270, PRIDE:PXD030304, Progenetix:CVCL_1562, PubChem_Cell_line:CVCL_1562, Wikidata:Q54908054

ID: CVCL_1562

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260829T234743+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H446.

No alerts have been found for NCI-H446.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 163 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Dutta Chowdhury D, et al. (2026) TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancer. *Molecular cancer therapeutics*.

Yoshikawa R, et al. (2026) Novel therapeutic strategy targeting STMN1 using chlorambucil-conjugated pyrrole-imidazole polyamide in small cell lung cancer. *International journal of cancer*, 158(5), 1336.

Cai G, et al. (2025) UMP functions as an endogenous regulator of NR4A1 to control gastric cancer progression. *Molecular cell*, 85(23), 4347.

Ryan PJ, et al. (2025) ATG4B is required for mTORC1-mediated anabolic activity and is associated with clinical outcomes in non-small cell lung cancer. *FEBS open bio*.

Fu X, et al. (2025) A cancer-specific antigen drives histone acetylation by stabilizing the acetyltransferases. *Cell reports*, 44(10), 116408.

Zhou W, et al. (2025) A public data-based molecular classification of small cell lung cancer by neuroactive signaling networks unveils distinct microenvironment landscapes and immunotherapy-related prognostic biomarkers. *Translational lung cancer research*, 14(11), 4983.

De Rosa C, et al. (2025) DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. *iScience*, 28(3), 111943.

Guo Y, et al. (2024) Design, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer agents. *Pharmaceutical biology*, 62(1), 233.

Lakhani NJ, et al. (2024) First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(3), 506.

Chakraborty S, et al. (2024) Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. *Cell reports. Medicine*, 5(12), 101852.

Ng J, et al. (2024) Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, OF1.

Kinoshita S, et al. (2024) Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer. *Cancer research communications*, 4(3), 723.

Zhou L, et al. (2024) A novel cancer-germline gene DAZL promotes progression and cisplatin resistance of non-small cell lung cancer by upregulating JAK2 and MCM8. *Gene*, 916, 148449.

Amato L, et al. (2024) Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study. *Cancers*, 16(18).

Li Y, et al. (2023) A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycle. *Journal of translational medicine*, 21(1), 422.

Sparbier CE, et al. (2023) Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes. *Nature cell biology*, 25(2), 258.

Deng L, et al. (2023) Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening. *Cell death discovery*, 9(1), 40.

Bryant JD, et al. (2023) Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression. *Molecular therapy oncolytics*, 28, 321.

Cannell IG, et al. (2023) FOXC2 promotes vasculogenic mimicry and resistance to anti-angiogenic therapy. *Cell reports*, 42(8), 112791.

Duan XH, et al. (2022) HuR affects chemoresistance of small cell lung cancer by regulating FGFR1 expression. *Experimental and therapeutic medicine*, 24(4), 638.